DOI: 10.25934/pr00011465
title: Tirzepatide and Systolic Blood Pressure: An Individual Patient Metaanalysis

description: High blood pressure (also known as hypertension) is a widespread health condition affecting over one billion people globally. It is a condition where the force of blood pushing against the artery walls is consistently too high. It increases the risk of serious complications such as heart attacks, strokes, and kidney disease. While several medications are available to manage blood pressure, treatment responses can vary between individuals, and there has been limited innovation in blood pressure therapies over the past two decades.

Tirzepatide is a new medication developed to treat type 2 diabetes (when the body doesn’t produce enough of a hormone called insulin or it doesn’t work properly causing high levels of sugar in the blood), and support weight loss. It works by mimicking two natural hormones in the body: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones help regulate blood sugar levels and reduce appetite. Interestingly, clinical studies have shown that tirzepatide also lowers blood pressure, even though it was not originally designed for that purpose.

The reasons for this blood pressure reduction are not yet fully understood. It is unclear whether the improvement is simply a result of weight loss, or whether tirzepatide also has direct effects on blood vessels or other systems involved in blood pressure regulation. Moreover, there is growing evidence that men and women may respond differently to blood pressure treatments due to biological and hormonal differences. However, sex-specific effects are often underreported in clinical trials.

This research aims to address these knowledge gaps by analyzing individual-level data from large, high-quality clinical trials of tirzepatide. These trials involved thousands of adults with obesity, type 2 diabetes, or related cardiovascular risk factors. By using an approach called an individual participant data meta-analysis, we will combine and re-analyze detailed data from several studies to examine:
1. How systolic blood pressure, the maximal pressure in the arteries when the heart contracts and pumps blood out (measured and displayed as the top number in a blood pressure reading) changes after treatment with tirzepatide
2. Whether responses differ between men and women
3. The relationship between weight loss and blood pressure change
4. Whether patients were able to reduce or stop other blood pressure medications
5. We will also assess how factors such as age, body mass index (BMI), and baseline blood pressure influence treatment effects.

The findings from this study will enhance our understanding of tirzepatide's effects on blood pressure, including potential sex-specific differences in its impact. This may help improve future clinical guidelines and support more personalized approaches to care.

This study will be conducted by an interdisciplinary team based at the University Medical Center Hamburg-Eppendorf in Germany. The results will be published in peer-reviewed journals and shared in accessible formats for the public.